Western lifestyle and immunopathology of multiple sclerosis

Annals of the New York Academy of Sciences

Volumn 1417, Issue 1, 2018, Pages 71-86

  Matveeva, Olga ^a   Bogie, Jeroen F J ^a   Hendriks, Jerome J A ^a   Linker, Ralf A ^b   Haghikia, Aiden ^c   Kleinewietfeld, Markus ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Diet; Environmental risk factors; FOXP3+ Treg cells; Multiple sclerosis; TH17 cells; Western lifestyle

Indexed keywords

FLAVONOID; MELATONIN; SATURATED FATTY ACID; SODIUM CHLORIDE; UNSATURATED FATTY ACID;

AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; ENVIRONMENTAL FACTOR; FAT INTAKE; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; LIFESTYLE; MULTIPLE SCLEROSIS; PATHOGENESIS; REVIEW; RISK FACTOR; SHIFT WORK; SLEEP; WESTERN DIET;

EID: 85041049183     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13583     Document Type: Review

References (193)

1. Browne, P., D. Chandraratna, C. Angood, et al. 2014. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology 83: 1022-1024.
2. Nylander, A. & D.A. Hafler. 2012.Multiple sclerosis. J. Clin. Invest. 122: 1180-1188.
3. Olsson, T., L.F. Barcellos & L. Alfredsson. 2017. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13: 25-36.
4. Hewer, S., R. Lucas, I. van der Mei, et al. 2013. Vitamin D and multiple sclerosis. J. Clin. Neurosci. 20: 634-641.
5. Belbasis, L., V. Bellou, E. Evangelou, et al. 2015. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 14: 263-273.
6. Sospedra, M. & R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
7. Langrish, C.L., Y. Chen, W.M. Blumenschein, et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
8. Petermann, F. & T. Korn. 2011. Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett. 585: 3747-3757.
9. Kebir, H., K. Kreymborg, I. Ifergan, et al. 2007. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13: 1173-1175.
10. Tzartos, J.S., M.A. Friese, M.J. Craner, et al. 2008. Interleukin-17 production in central nervous system infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172: 146-155.
11. Brucklacher-Waldert, V., K. Stuerner, M. Kolster, et al. 2009. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132: 3329-3341.
12. Darlington, P.J., T. Touil, J.S. Doucet, et al. 2013. Diminished Th17 (not Th1) responses underliemultiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann. Neurol. 73: 341-354.
13. Skulina, C., S. Schmidt, K. Dornmair, et al. 2004. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. USA 101: 2428-2433.
14. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169: 4712-4716.
15. Kohm, A.P., J.S. McMahon, J.R. Podojil, et al. 2006. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 176: 3301-3305.
16. Kleinewietfeld, M. & D.A. Hafler. 2014. Regulatory T cells in autoimmune neuroinflammation. Immunol. Rev. 259: 231-244.
17. Kleinewietfeld, M. & D.A. Hafler. 2013. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin. Immunol. 25: 305-312.
18. Sellebjerg, F., M. Krakauer, M. Khademi, et al. 2012. FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis. Clin. Exp. Immunol. 170: 149-155.
19. Venken, K., N. Hellings, M. Thewissen, et al. 2008. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79-89.
20. Kappos, L., D. Li, P.A. Calabresi, et al. 2011. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779-1787.
21. CAMMS223 Trial Investigators, A.J. Coles, D.A. Composton, et al. 2008. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359: 1786-1801.
22. Coles, A.J., E. Fox, A. Vladic, et al. 2012. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78: 1069-1078.
23. Hawker, K., P. O’Connor, M.S. Freedman, et al. 2009. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebocontrolled multicenter trial. Ann. Neurol. 66: 460-471.
24. Hauser, S.L., G.C. Comi & H.-P. Hartung. 2015. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis— results of the interferon-beta-1a-controlled, double blind, phase III OPERA I and II studies. Mult. Scler. 21(S11): 61-62.
25. Montalban, X., B. Hemmer, K. Rammohan, et al.; ORATORIO Clinical Investigators. 2015. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis— results of the placebo-controlled, double-blind, phase III ORATORIO study. ECTRIMSCongress, Barcelona, abstract 228.
26. Magliozzi, R., O. Howell, A. Vora, et al. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104.
27. Cepok, S., B. Rosche, V. Grummel, et al. 2005. Shortlived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128: 1667-1676.
28. Kuenz, B., A. Lutterotti, R. Ehling, et al. 2008.Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 3: e2559.
29. Howell, O.W., J.L. Rundle, A. Garg, et al. 2010. Activated microglia mediate axoglial disruption that contributes to axonal injury inmultiple sclerosis. J. Neuropathol. Exp.Neurol. 69: 1017-1033.
30. + mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. 159: 1701-1710.
31. Bogie, J.F., P. Stinissen & J.J. Hendriks. 2014. Macrophage subsets and microglia in multiple sclerosis. Acta Neuropathol. 128: 191-213.
32. Politis, M., P. Giannetti, P. Su, et al. 2012. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 79: 523-530.
33. Bogie, J.F., W. Jorissen, J. Mailleux, et al. 2013.Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol. Commun. 1: 43.
34. Bogie, J.F., S. Timmermans, V.A. Huynh-Thu, et al. 2012. Myelin-derived lipids modulate macrophage activity by liver X receptor activation. PLoS One 7: e44998.
35. Shimonkevitz, R., C. Colburn, J.A. Burnham, et al. 1993. Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis. Proc. Natl. Acad. Sci. USA 90: 923-927.
36. + γδ T cells in the cerebrospinal fluid of patients with multiple sclerosis. JAMA Neurol. 70: 345-351.
37. Plantone, D., A. Marti, G. Frisullo, et al. 2013. Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. J. Neuroimmunol. 265: 124-127.
38. Rodriguez-Martin, E., C. Picon, L. Costa-Frossard, et al. 2015. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin. Exp. Immunol. 180: 243-249.
39. Gross, C.C., A. Schulte-Mecklenbeck, U. Hanning, et al. 2017. Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. Mult. Scler. 23: 1025-1030.
40. Abrahamsson, S.V., D.F. Angelini, A.N. Dubinsky, et al. 2013. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136: 2888-2903.
41. Illes, Z., M. Shimamura, J. Newcombe, et al. 2004. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int. Immunol. 16: 223-230.
42. Miyazaki, Y., S. Miyake, A. Chiba, et al. 2011. Mucosalassociated invariant T cells regulate Th1 response in multiple sclerosis. Int. Immunol. 23: 529-535.
43. Bianchini, E., S. De Biasi, A.M. Simone, et al. 2017. Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunol. Lett. 183: 1-7.
44. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, S. Sawcer, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
45. Taylor, B.V. 2011. The major cause of multiple sclerosis is environmental: genetics has a minor role—yes. Mult. Scler. 17: 1171-1173.
46. Moutsianas, L., L. Jostins, A.H. Beecham, et al. 2015. Class II HLA interactionsmodulate genetic risk formultiple sclerosis. Nat. Genet. 47: 1107-1113.
47. International Multiple Sclerosis Genetics Consortium (IMSGC), A.H. Beecham, N.A. Patsopoulos, et al. 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45: 1353-1360.
48. Patsopoulos, N.A., International Multiple Sclerosis Genetics Consortium. 2016. 200 loci complete the genetic puzzle of multiple sclerosis. In American Society of Human Genetics 2016 Annual Meeting, Vancouver, BC, Canada.
49. Farh, K.K., A. Marson, J. Zhu, et al. 2015. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518: 337-343.
50. Willer, C.J., D.A. Dyment, N.J. Risch, et al. 2003. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. USA 100: 12877-12882.
51. Mumford, C.J., N.W. Wood, H. Kellar-Wood, et al. 1994. The British Isles survey of multiple sclerosis in twins. Neurology 44: 11-15.
52. French Research Group on Multiple Sclerosis. 1992. Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity. French Research Group on Multiple Sclerosis. Ann. Neurol. 32: 724-727.
53. Ristori, G., S. Cannoni, M.A. Stazi, et al. 2006. Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study. Ann. Neurol. 59: 27-34.
54. Ebers, G.C., A.D. Sadovnick & N.J. Risch. 1995. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377: 150-151.
55. Berg-Hansen, P., S.M. Moen, L. Sandvik, et al. 2015. Prevalence of multiple sclerosis among immigrants in Norway. Mult. Scler. 21: 695-702.
56. Kurtzke, J.F., G.W. Beebe & J.E. Norman Jr. 1985. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 35: 672-678.
57. McLeod, J.G., S.R. Hammond & J.F. Kurtzke. 2011.Migration andmultiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J. Neurol. 258: 1140-1149.
58. Dean, G. & J.F. Kurtzke. 1971. On the risk of multiple sclerosis according to age at immigration to South Africa. Br. Med. J. 3: 725-729.
59. Orton, S.M., S.V. Ramagopalan, D. Brocklebank, et al. 2010. Effect of immigration on multiple sclerosis sex ratio in Canada: the Canadian Collaborative Study. J. Neurol. Neurosurg. Psychiatry 81: 31-36.
60. Mokry, L.E., S. Ross, N.J. Timpson, et al. 2016.Obesity and multiple sclerosis: aMendelian randomization study. PLoS Med. 13: e1002053.
61. Langer-Gould, A., S.M. Brara, B.E. Beaber, et al. 2013. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 80: 548-552.
62. Hedström, A.K., T. Olsson & L. Alfredsson. 2012. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18: 1334-1336.
63. Berer, K., M. Mues, M. Koutrolos, et al. 2011. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479: 538-541.
64. Ochoa-Reparaz, J., D.W. Mielcarz, L.E. Ditrio, et al. 2009. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J. Immunol. 183: 6041-6050.
65. Lee, Y.K., J.S. Menezes, Y. Umesaki, et al. 2011. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 108(Suppl. 1): 4615-4622.
66. Ivanov, I.I., K. Atarashi, N. Manel, et al. 2009. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485-498.
67. Jangi, S., R. Gandhi, L.M. Cox, et al. 2016. Alterations of the human gutmicrobiome in multiple sclerosis. Nat.Commun. 7: 12015.
68. Tremlett, H., D.W. Fadrosh, A.A. Faruqi, et al. 2016. Gut microbiota composition and relapse risk in pediatric MS: a pilot study. J. Neurol. Sci. 363: 153-157.
69. Miyake, S., S. Kim, W. Suda, et al. 2015. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One 10: e0137429.
70. Cosorich, I., G. Dalla-Costa, C. Sorini, et al. 2017. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci. Adv. 3: e1700492.
71. Rothhammer, V., I.D. Mascanfroni, L. Bunse, et al. 2016. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22: 586-597.
72. Rothhammer, V., D.M. Borucki, M.I. Garcia Sanchez, et al. 2017. Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. Neurol. Neuroimmunol. Neuroinflamm. 4: e359.
73. Mozaffarian, D., S. Fahimi, G.M. Singh, et al. 2014. Global sodium consumption and death from cardiovascular causes. N. Engl. J. Med. 371: 624-634.
74. Kleinewietfeld, M., A. Manzel, J. Titze, et al. 2013. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496: 518-522.
75. Wu, C., N. Yosef, T. Thalhamer, et al. 2013. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496: 513-517.
76. Farez, M.F., M.P. Fiol, M.I. Gaitan, et al. 2015. Sodium intake is associated with increased disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 86: 26-31.
77. Hucke, S., M. Eschborn, M. Liebmann, et al. 2016. Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. J. Autoimmun. 67: 90-101.
78. Jorg, S., J. Kissel, A. Manzel, et al. 2016. High salt drives TH17 responses in experimental autoimmune encephalomyelitis without impacting myeloid dendritic cells. Exp. Neurol. 279: 212-222.
79. Krementsov, D.N., L.K. Case, W.F. Hickey, et al. 2015. Exacerbation of autoimmune neuroinflammation by dietary sodium is genetically controlled and sex specific. FASEB J. 29: 3446-3457.
80. Salgado, E., M. Bes-Rastrollo, J. de Irala, et al. 2015. High sodium intake is associated with self-reported rheumatoid arthritis: a cross sectional and case control analysis within the SUN cohort. Medicine 94: e924.
81. Wu, H., X. Huang, H. Qiu, et al. 2016. High salt promotes autoimmunity by TET2-induced DNA demethylation and driving the differentiation of Tfh cells. Sci. Rep. 6: 28065.
82. Yang, X., G. Yao, W. Chen, et al. 2015. Exacerbation of lupus nephritis by high sodium chloride related to activation of SGK1 pathway. Int. Immunopharmacol. 29: 568-573.
83. Yi, B., J. Titze, M. Rykova, et al. 2015. Effects of dietary salt levels on monocytic cells and immune responses in healthy human subjects: a longitudinal study. Transl. Res. 166: 103-110.
84. Fitzgerald, K.C., K.L. Munger, H.P. Hartung, et al. 2017. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann. Neurol. 82: 20-29
85. Hernandez, A.L., A. Kitz, C. Wu, et al. 2015. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J. Clin. Invest. 125: 4212-4222.
86. Jantsch, J., V. Schatz, D. Friedrich, et al. 2015. Cutaneous Na+ storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defense. Cell Metab. 21: 493-501.
87. Binger, K.J., M. Gebhardt, M. Heinig, et al. 2015. High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J. Clin. Invest. 125: 4223-4238.
88. Ip, W.K. & R. Medzhitov. 2015. Macrophages monitor tissue osmolarity and induce inflammatory response through NLRP3 and NLRC4 inflammasome activation. Nat. Commun. 6: 6931.
89. Zhou, X., L. Zhang, W.J. Ji, et al. 2013. Variation in dietary salt intake induces coordinated dynamics of monocyte subsets and monocyte-platelet aggregates in humans: implications in end organ inflammation. PLoS One 8: e60332.
90. Zhang, T., S. Fang, C. Wan, et al. 2015. Excess salt exacerbates blood-brain barrier disruption via a p38/MAPK/SGK1-dependent pathway in permanent cerebral ischemia. Sci. Rep. 5: 16548.
91. Timmermans, S., J.F. Bogie, T. Vanmierlo, et al. 2014. High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the renin angiotensin system. J. Neuroimmune Pharmacol. 9: 209-217.
92. Swank, R.L., O. Lerstad, A. Strom, et al. 1952. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 246: 722-728.
93. Alter, M., M. Yamoor & M. Harshe. 1974.Multiple sclerosis and nutrition. Arch. Neurol. 31: 267-272.
94. Lauer, K. 1997. Diet and multiple sclerosis. Neurology 49: S55-S61.
95. Zhang, S.M., W.C. Willett, M.A. Hernan, et al. 2000. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am. J. Epidemiol. 152: 1056-1064.
96. Schwarz, S. & H. Leweling. 2005. Multiple sclerosis and nutrition. Mult. Scler. 11: 24-32.
97. Winer, S., G. Paltser, Y. Chan, et al. 2009. Obesity predisposes to Th17 bias. Eur. J. Immunol. 39: 2629-2635.
98. Haghikia, A., S. Jorg, A. Duscha, et al. 2015. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity 43: 817-829.
99. Wang, C., N. Yosef, J. Gaublomme, et al. 2015. CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell 163: 1413-1427.
100. Huang, S., J.M. Rutkowsky, R.G. Snodgrass, et al. 2012. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J. Lipid Res. 53: 2002-2013.
101. Yan, Y., W. Jiang, T. Spinetti, et al. 2013. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38: 1154-1163.
102. Allen, M.J., Y.Y. Fan, J.M. Monk, et al. 2014. n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4(+) T cells. J. Nutr. 144: 1306-1313.
103. Singh, I. & A. Pujol. 2010. Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol. 20: 838-844.
104. Swank, R.L. & J.W. Goodwin. 2003.Howsaturated fats may be a causative factor inmultiple sclerosis and other diseases. Nutrition 19: 478.
105. Mani, V., J.H. Hollis & N.K. Gabler. 2013. Dietary oil composition differentially modulates intestinal endotoxin transport and postprandial endotoxemia. Nutr. Metab. 10: 6.
106. Davila, E. & J. Kolls. 2010. A “Toll” for Th17 cell expansion. J. Leukoc. Biol. 88: 5-7.
107. McAleer, J.P. & A.T. Vella. 2008. Understanding how lipopolysaccharide impacts CD4 T-cell immunity. Crit. Rev. Immunol. 28: 281-299.
108. Qin, L., X. Wu, M.L. Block, et al. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
109. Rivest, S. 2009. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 9: 429-439.
110. Siri-Tarino, P.W., Q. Sun, F.B. Hu, et al. 2010. Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. Curr. Atheroscler. Rep. 12: 384-390.
111. Tall, A.R. & L. Yvan-Charvet. 2015. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15: 104-116.
112. Lim, H., Y.U. Kim, H. Sun, et al. 2014. Proatherogenic conditions promote autoimmune Thelper 17 cell responses in vivo. Immunity 40: 153-165.
113. Bjornevik, K., T. Chitnis, A. Ascherio, et al. 2017. Polyunsaturated fatty acids and the risk ofmultiple sclerosis. Mult. Scler. 23: 1830-1838.
114. Hoare, S., F. Lithander, I. van der Mei, et al. 2016. Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: results from the Ausimmune Study. Mult. Scler. 22: 884-892.
115. Schmitz, G. & J. Ecker. 2008. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47: 147-155.
116. Ferrante, A., D. Goh, D.P. Harvey, et al. 1994. Neutrophil migration inhibitory properties of polyunsaturated fatty acids. The role of fatty acid structure, metabolism, and possible secondmessenger systems. J. Clin. Invest. 93: 1063-1070.
117. Siegert, E., F. Paul, M. Rothe, et al. 2017. The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. BMC Neurosci. 18: 19.
118. Kohli, P. & B.D. Levy. 2009. Resolvins and protectins: mediating solutions to inflammation.Br. J. Pharmacol. 158: 960-971.
119. Basil, M.C. & B.D. Levy. 2016. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 16: 51-67.
120. Sakata, D., C. Yao & S. Narumiya. 2010. Prostaglandin E2, an immunoactivator. J. Pharmacol. Sci. 112: 1-5.
121. Calviello, G., H.M. Su, K.H. Weylandt, et al. 2013. Experimental evidence of omega-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed. Res. Int. 2013: 743171.
122. Farinotti, M., L. Vacchi, S. Simi, et al. 2012. Dietary interventions formultiple sclerosis. Cochrane Database Syst. Rev. 12: CD004192.
123. Harbige, L.S., L. Layward, M.M. Morris-Downes, et al. 2000. The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) upregulation and increased prostaglandin E2 (PGE2) production. Clin. Exp. Immunol. 122: 445-452.
124. Okada, Y., Y. Tsuzuki, T. Ueda, et al. 2013. Trans fatty acids in diets act as a precipitating factor for gut inflammation? J. Gastroenterol. Hepatol. 28(Suppl. 4): 29-32.
125. Marino, E., J.L. Richards, K.H. McLeod, et al. 2017. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18: 552-562.
126. Smith, P.M., M.R. Howitt, N. Panikov, et al. 2013. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569-573.
127. Furusawa, Y., Y. Obata, S. Fukuda, et al. 2013. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446-450.
128. Wang, L., E.F. de Zoeten, M.I. Greene, et al. 2009. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug Discov. 8: 969-981.
129. Sonnenburg, J.L. & F. Backhed. 2016. Diet-microbiota interactions as moderators of human metabolism. Nature 535: 56-64.
130. U.S. Food & Drug Administration. 2016. CFR—Code of Federal Regulations Title 21. September 21, 2016. Accessed April 21, 2017. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1081.
131. EFSA Panel on Food Additives andNutrient Sources added to Food (ANS). 2016. Safety of the extension of use of sodium propionate (E 281) as a food additive. EFSA J. 14: 4546-4559.
132. Alvarez-Curto, E. & G. Milligan. 2016. Metabolism meets immunity: the role of free fatty acid receptors in the immune system. Biochem. Pharmacol. 114: 3-13.
133. Bouchard, C., J. Page, A. Bedard, et al. 2007. G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia 55: 790-800.
134. Nicol, L.S., J.M. Dawes, F. La Russa, et al. 2015. The role of G-protein receptor 84 in experimental neuropathic pain. J. Neurosci. 35: 8959-8969.
135. Brites, P., P.A. Mooyer, L. El Mrabet, et al. 2009. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 132: 482-492.
136. Paintlia, A.S., A.G. Gilg, M. Khan, et al. 2003.Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol. Dis. 14: 425-439.
137. Yanagisawa, N., K. Shimada, T. Miyazaki, et al. 2008. Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages. Lipids Health Dis. 7: 48.
138. Weber, F.D., C. Wiesinger, S. Forss-Petter, et al. 2014. Xlinked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. Hum. Mol. Genet. 23: 2542-2550.
139. Wilkins, A., G. Ingram, A. Brown, et al. 2009. Very long chain fatty acid levels in patients diagnosed with multiple sclerosis. Mult. Scler. 15: 1525-1527.
140. Kumar, S. & A.K. Pandey. 2013. Chemistry and biological activities of flavonoids: an overview. Sci. World J. 2013: 162750.
141. Rothwell, J.A., J. Perez-Jimenez, V. Neveu, et al. 2013. Phenol-Explorer 3.0: a major update of the Phenol- Explorer database to incorporate data on the effects of food processing on polyphenol content. Database 2013: bat070.
142. Cheng-Chung Wei, J., H.C. Huang, W.J. Chen, et al. 2016. Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia. Eur. J. Pharmacol. 770: 16-24.
143. Endale, M., S.C. Park, S. Kim, et al. 2013. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3- kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells. Immunobiology 218: 1452-1467.
144. Manjeet, K.R. & B. Ghosh. 1999. Quercetin inhibits LPSinduced nitric oxide and tumor necrosis factor-alpha production inmurinemacrophages. Int. J. Immunopharmacol. 21: 435-443.
145. Sun, G.Y., Z. Chen, K.J. Jasmer, et al. 2015. Quercetin attenuates inflammatory responses in BV-2microglial cells: role of MAPKs on the Nrf2 pathway and induction of heme oxygenase-1. PLoS One 10: e0141509.
146. Hendriks, J.J., H.E. de Vries, S.M. van der Pol, et al. 2003. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. Biochem. Pharmacol. 65: 877-885.
147. Hendriks, J.J., J. Alblas, S.M. van der Pol, et al. 2004. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp.Med. 200: 1667-1672.
148. Sternberg, Z., K. Chadha, A. Lieberman, et al. 2008. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J. Neuroimmunol. 205: 142-147.
149. Singh, N.P., V.L. Hegde, L.J. Hofseth, et al. 2007. Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 72: 1508-1521.
150. Aktas, O., T. Prozorovski, A. Smorodchenko, et al. 2004. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173: 5794-5800.
151. Muthian, G. & J.J. Bright. 2004. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol. 24: 542-552.
152. Wang, D., S.P. Li, J.S. Fu, et al. 2016. Resveratrol defends blood-brain barrier integrity in experimental autoimmune encephalomyelitis mice. J. Neurophysiol. 116: 2173-2179.
153. Zhang, Y., X. Li, B. Ciric, et al. 2015. Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci. Rep. 5: 17407.
154. Ginwala, R., E. McTish, C. Raman, et al. 2016. Apigenin, a natural flavonoid, attenuates EAE severity through the modulation of dendritic cell and other immune cell functions. J. Neuroimmune Pharmacol. 11: 36-47.
155. Liang, M., Y. Chen, L. Zhang, et al. 2015. Epimedium flavonoids ameliorate neuropathological changes and increases IGF-1 expression in C57BL/6 mice exposed to cuprizone. Neurochem. Res. 40: 492-500.
156. Wang, W.W., L. Lu, T.H. Bao, et al. 2016. Scutellarin alleviates behavioral deficits in a mouse model of multiple sclerosis, possibly through protecting neural stem cells. J. Mol. Neurosci. 58: 210-220.
157. Lovera, J., A. Ramos, D. Devier, et al. 2015. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: phase I single group and phase II randomized placebo-controlled studies. J. Neurol. Sci. 358: 46-52.
158. Costa, G., T. Akerstedt, F. Nachreiner, et al. 2004. Flexible working hours, health, and well-being in Europe: some considerations from a SALTSA project. Chronobiol. Int. 21: 831-844.
159. Costa, G. 2010. Shift work and health: current problems and preventive actions. Saf. Health Work 1: 112-123.
160. Li, W.Q., A.A. Qureshi, E.S. Schernhammer, et al. 2013. Rotating night-shift work and risk of psoriasis in US women. J. Invest. Dermatol. 133: 565-567.
161. Puttonen, S., T. Oksanen, J. Vahtera, et al. 2010. Is shift work a risk factor for rheumatoid arthritis? The Finnish Public Sector study. Ann. Rheum. Dis. 69: 779-780.
162. Cooper, G.S., C.G. Parks, E.L. Treadwell, et al. 2004. Occupational risk factors for the development of systemic lupus erythematosus. J. Rheumatol. 31: 1928-1933.
163. Magrini, A., A. Pietroiusti, L. Coppeta, et al. 2006. Shift work and autoimmune thyroid disorders. Int. J. Immunopathol. Pharmacol. 19: 31-36.
164. Hedström, A.K., T. Akerstedt, J. Hillert, et al. 2011. Shift work at young age is associated with increased risk for multiple sclerosis. Ann. Neurol. 70: 733-741.
165. Hedström, A.K., T. Akerstedt, T. Olsson, et al. 2015. Shift work influences multiple sclerosis risk. Mult. Scler. 21: 1195-1199.
166. Gustavsen, S., H.B. Sondergaard, D.B. Oturai, et al. 2016. Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population. Mult. Scler. Relat. Disord. 9: 104-109.
167. Lowrey, P.L. & J.S. Takahashi. 2011. Genetics of circadian rhythms in Mammalian model organisms. Adv. Genet. 74: 175-230.
168. Zhu, Y., R.G. Stevens, A.E. Hoffman, et al. 2011. Epigenetic impact of long-term shiftwork: pilot evidence from circadian genes and whole-genome methylation analysis. Chronobiol. Int. 28: 852-861.
169. Bracci, M., N. Manzella, A. Copertaro, et al. 2014.Rotatingshift nurses after a day off: peripheral clock gene expression, urinarymelatonin, and serum17-β-estradiol levels. Scand. J. Work Environ. Health 40: 295-304.
170. Huynh, J.L., P. Garg, T.H. Thin, et al. 2014.Epigenome-wide differences in pathology-free regions of multiple scleros is affected brains. Nat. Neurosci. 17: 121-130.
171. Buenafe, A.C., H. Zwickey, N. Moes, et al. 2008. A telemetric study of physiologic changes in mice with induced autoimmune encephalomyelitis. Lab. Anim. 37: 361-368.
172. Buenafe, A.C. 2012. Diurnal rhythms are altered in amouse model of multiple sclerosis. J. Neuroimmunol. 243: 12-17.
173. Druzd, D., O. Matveeva, L. Ince, et al. 2017. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. Immunity 46: 120-132. inflammation and neurotoxicity in EOC 13.31 microglia. Eur. J. Pharmacol. 770: 16-24.
174. Bamer, A.M., K.L. Johnson, D. Amtmann, et al. 2008. Prevalence of sleep problems in individuals with multiple sclerosis. Mult. Scler. 14: 1127–1130.
175. Boe Lunde, H.M., T.F. Aae, W. Indrevag, et al. 2012. Poor sleep in patients with multiple sclerosis. PLoS One 7: e49996.
176. Tachibana, N., R.S. Howard, N.P. Hirsch, et al. 1994. Sleep problems in multiple sclerosis. Eur. Neurol. 34: 320-323.
177. Najafi, M.R., N. Toghianifar, M. Etemadifar, et al. 2013. Circadian rhythm sleep disorders in patients with multiple sclerosis and its association with fatigue: a case–control study. J. Res. Med. Sci. 18: S71–S73.
178. He, J., H. Hsuchou, Y. He, et al. 2014. Leukocyte infiltration across the blood–spinal cord barrier is modulated by sleep fragmentation in mice with experimental autoimmune encephalomyelitis. Fluids Barriers CNS 11: 27.
179. Figueiro, M.G., A. Bierman & M.S. Rea. 2013. A train of blue light pulses delivered through closed eyelids suppresses melatonin and phase shifts the human circadian system. Nat. Sci. Sleep 5: 133–141.
180. Trinder, J., S.M. Armstrong, C. O’Brien, et al. 1996. Inhibition of melatonin secretion onset by low levels of illumination. J. Sleep Res. 5: 77–82.
181. Reiter, R.J. 1993. The melatonin rhythm: both a clock and a calendar. Experientia 49: 654–664.
182. Ghorbani, A., M. Salari, V. Shaygannejad, et al. 2013. The role of melatonin in the pathogenesis of multiple sclerosis: a case–control study. Int. J. Prev. Med. 4: S180–S184.
183. Melamud, L., D. Golan, R. Luboshitzky, et al. 2012. Melatonin dysregulation, sleep disturbances and fatigue inmultiple sclerosis. J. Neurol. Sci. 314: 37–40.
184. Gholipour, T., T. Ghazizadeh, S. Babapour, et al. 2015. Decreased urinary level ofmelatonin as amarker of disease severity in patients with multiple sclerosis. Iran J. Allergy Asthma Immunol. 14: 91–97.
185. Damasceno, A., A.S. Moraes, A. Farias, et al. 2015. Disruption of melatonin circadian rhythm production is related tomultiple sclerosis severity: a preliminary study. J.Neurol. Sci. 353: 166–168.
186. Constantinescu, C.S., B. Hilliard, E. Ventura, et al. 1997. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 65: 190–194.
187. Ghareghani, M., S. Dokoohaki, A. Ghanbari, et al. 2017. Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: a potential biomarker of multiple sclerosis progression. Clin. Exp. Pharmacol. Physiol. 44: 52–61.
188. Alvarez-Sanchez, N., I. Cruz-Chamorro, A. Lopez- Gonzalez, et al. 2015. Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/ regulatory balance. Brain Behav. Immun. 50: 101–114.
189. Kang, J.C., M. Ahn, Y.S. Kim, et al. 2001. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J. Vet. Sci. 2: 85-89.
190. Chen, S.J., S.H. Huang, J.W. Chen, et al. 2016. Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis. Int. Immunopharmacol. 31: 169–177.
191. Farez, M.F., I.D. Mascanfroni, S.P. Mendez-Huergo, et al. 2015. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162: 1338–1352.
192. Wen, J., P.S. Ariyannur, R. Ribeiro, et al. 2016. Efficacy of N-acetylserotonin and melatonin in the EAE model of multiple sclerosis. J. Neuroimmune Pharmacol. 11: 763-773.
193. Lopez-Gonzalez, A., N. Alvarez-Sanchez, P.J. Lardone, et al. 2015. Melatonin treatment improves primary progressive multiple sclerosis: a case report. J. Pineal Res. 58: 173–177.